Search Results

You are looking at 1 - 7 of 7 items for :

Clear All
Open access

Kjell Oberg, Eric Krenning, Anders Sundin, Lisa Bodei, Mark Kidd, Margot Tesselaar, Valentina Ambrosini, Richard P Baum, Matthew Kulke, Marianne Pavel, Jaroslaw Cwikla, Ignat Drozdov, Massimo Falconi, Nicola Fazio, Andrea Frilling, Robert Jensen, Klaus Koopmans, Tiny Korse, Dik Kwekkeboom, Helmut Maecke, Giovanni Paganelli, Ramon Salazar, Stefano Severi, Jonathan Strosberg, Vikas Prasad, Aldo Scarpa, Ashley Grossman, Annemeik Walenkamp, Mauro Cives, Irene Virgolini, Andreas Kjaer and Irvin M Modlin

Response Evaluation Criteria in Solid T umor s (RECIST) criteria exhibits well-documented limitations ( 18 , 19 , 20 ). These include issues with lesion dimensionality and measurements thereof, effects of therapy on lesion appearance itself, difficulties

Open access

Anna Malczewska, Magdalena Witkowska, Karolina Makulik, Agnes Bocian, Agata Walter, Joanna Pilch-Kowalczyk, Wojciech Zajęcki, Lisa Bodei, Kjell Oberg and Beata Kos-Kudła

restrictions ( 9 , 10 ). Imaging remains a key component of diagnostic work-up or disease monitoring, for example, identification of disease status or therapeutic efficacy ( 11 ). RECIST and RECIST 1.1 criteria, most-widely used for the assessment of

Open access

Yang Lv, Xu Han, Chunyan Zhang, Yuan Fang, Ning Pu, Yuan Ji, Dansong Wang, Xu Xuefeng and Wenhui Lou

response (PR), stable disease (SD), progressive disease (PD), progression, relapse and distant metastasis on the basis of response evaluation criteria in solid tumors (RECIST 1.1) ( 12 ) to assess the treatment response. The data of preoperative clinical

Open access

Kosmas Daskalakis, Marina Tsoli, Anna Angelousi, Evanthia Kassi, Krystallenia I Alexandraki, Denise Kolomodi, Gregory Kaltsas and Anna Koumarianou

Tumors (RECIST) ( 14 ). Patients were selected for MTT initiation with either everolimus or sunitinib after central assessment of cross-sectional imaging. The selection of first-line MTT therapy was based on international guidelines, but also on the

Open access

Martin Zweifel, Beat Thürlimann, Salome Riniker, Patrik Weder, Roger von Moos, Olivia Pagani, Martin Bigler, Karin M Rothgiesser, Christiane Pilop, Hanne Hawle, Peter Brauchli, Coya Tapia, Wolfgang Schoenfeld, Cristiana Sessa and for the Swiss Group for Clinical Cancer Research (SAKK)

2 (HER2) negative. Presence of ≥1 measurable or evaluable lesion according to RECIST 1.1 was required. Bone metastases were allowed to be considered as target lesions in case of enhancement on scintigraphy, cytologic/histologic evidence or typical

Open access

Anne Jouinot, Bernard Royer, Etienne Chatelut, Sotheara Moeung, Guillaume Assié, Audrey Thomas-Schoemann, Jérôme Bertherat, François Goldwasser and Benoit Blanchet

absence of limiting toxicity, a dose escalation of etoposide could be proposed from cycle 2. Efficacy was assessed by CT scan every three cycles. Objective responses that did not meet the Response Evaluation Criteria In Solid Tumors (RECIST) criteria were

Open access

Katerina Saltiki, Elli Anagnostou, George Simeakis, Sofia Kouki, Anastasia Angelopoulou, Leda Sarika, Alexandra Papathoma and Maria Alevizaki

post-operative calcitonin at 3 and 6 months, and yearly after the first surgery were evaluated and used to classify patients into three groups: remission, stable disease and progressive disease. According to RECIST criteria and calcitonin doubling time